DrugCite
Search

NOVATREX

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Novatrex Adverse Events Reported to the FDA Over Time

How are Novatrex adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Novatrex, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Novatrex is flagged as the suspect drug causing the adverse event.

Most Common Novatrex Adverse Events Reported to the FDA

What are the most common Novatrex adverse events reported to the FDA?

Interstitial Lung Disease
18 (1.97%)
Pancytopenia
17 (1.86%)
Pyrexia
17 (1.86%)
Drug Ineffective
15 (1.64%)
Asthenia
12 (1.31%)
Lung Disorder
12 (1.31%)
Anaemia
11 (1.2%)
Dyspnoea
11 (1.2%)
Cough
10 (1.09%)
General Physical Health Deteriorati...
10 (1.09%)
Tuberculosis
10 (1.09%)
Show More Show More
Alanine Aminotransferase Increased
9 (.98%)
Aspartate Aminotransferase Increase...
9 (.98%)
Condition Aggravated
9 (.98%)
Diarrhoea
9 (.98%)
Psoriasis
9 (.98%)
Blood Alkaline Phosphatase Increase...
8 (.87%)
Gamma-glutamyltransferase Increased
8 (.87%)
Lymph Node Tuberculosis
8 (.87%)
Renal Failure
8 (.87%)
Cytolytic Hepatitis
7 (.76%)
Rheumatoid Arthritis
7 (.76%)
Arthralgia
6 (.66%)
Confusional State
6 (.66%)
Drug Interaction
6 (.66%)
Headache
6 (.66%)
Hypoxia
6 (.66%)
Pneumonia Legionella
6 (.66%)
Alveolitis
5 (.55%)
Back Pain
5 (.55%)
Bone Marrow Failure
5 (.55%)
Bronchitis
5 (.55%)
Cardiac Failure
5 (.55%)
Drug Effect Decreased
5 (.55%)
Epiduritis
5 (.55%)
Haematuria
5 (.55%)
Infection
5 (.55%)
Oesophageal Ulcer
5 (.55%)
Phlebitis
5 (.55%)
Platelet Count Decreased
5 (.55%)
Pneumonia
5 (.55%)
Somnolence
5 (.55%)
T-cell Lymphoma Stage Iv
5 (.55%)
Thrombocytopenia
5 (.55%)
Weight Decreased
5 (.55%)
Acute Respiratory Distress Syndrome
4 (.44%)
Acute Sinusitis
4 (.44%)
Anaemia Macrocytic
4 (.44%)
Chest X-ray Abnormal
4 (.44%)
Colon Cancer
4 (.44%)
Cryptococcosis
4 (.44%)
Ecchymosis
4 (.44%)
Hemiplegia
4 (.44%)
Leukopenia
4 (.44%)
Lipoma
4 (.44%)
Lung Neoplasm Malignant
4 (.44%)
Neutropenia
4 (.44%)
T-cell Lymphoma
4 (.44%)
Acinetobacter Infection
3 (.33%)
Acute Coronary Syndrome
3 (.33%)
Agranulocytosis
3 (.33%)
Anorectal Disorder
3 (.33%)
Aspergillosis
3 (.33%)
Basal Cell Carcinoma
3 (.33%)
Breast Cancer
3 (.33%)
Colitis Ischaemic
3 (.33%)
Conjunctivitis
3 (.33%)
Coronary Artery Stenosis
3 (.33%)
Dementia
3 (.33%)
Demyelinating Polyneuropathy
3 (.33%)
Demyelination
3 (.33%)
Disorientation
3 (.33%)
Epstein-barr Virus Infection
3 (.33%)
Fall
3 (.33%)
Febrile Bone Marrow Aplasia
3 (.33%)
Folate Deficiency
3 (.33%)
Gastroenteritis
3 (.33%)
Hepatic Enzyme Increased
3 (.33%)
Hypertriglyceridaemia
3 (.33%)
Hypoalbuminaemia
3 (.33%)
Hypovolaemic Shock
3 (.33%)
Ileus
3 (.33%)
Inflammation
3 (.33%)
Ischaemic Stroke
3 (.33%)
Lung Neoplasm
3 (.33%)
Malaise
3 (.33%)
Metastases To Liver
3 (.33%)
Multiple Myeloma
3 (.33%)
Mycobacterium Avium Complex Infecti...
3 (.33%)
Myocardial Infarction
3 (.33%)
Oxygen Saturation Decreased
3 (.33%)
Post-traumatic Pain
3 (.33%)
Productive Cough
3 (.33%)
Prostatitis
3 (.33%)
Pulmonary Embolism
3 (.33%)
Pulmonary Fibrosis
3 (.33%)
Pyelonephritis
3 (.33%)
Renal Cell Carcinoma
3 (.33%)
Rhinitis
3 (.33%)
Serratia Infection
3 (.33%)
Traumatic Haematoma
3 (.33%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Novatrex, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Novatrex is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Novatrex

What are the most common Novatrex adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Novatrex, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Novatrex is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Novatrex According to Those Reporting Adverse Events

Why are people taking Novatrex, according to those reporting adverse events to the FDA?

Rheumatoid Arthritis
268
Psoriatic Arthropathy
22
Drug Use For Unknown Indication
18
Ankylosing Spondylitis
9
Psoriasis
8
Product Used For Unknown Indication
8
Show More Show More
Sarcoidosis
4
Polyarthritis
4
Crohns Disease
3
Temporal Arteritis
3
Systemic Lupus Erythematosus
2
Back Pain
2
Pemphigoid
2
Spondyloarthropathy
1
Pustular Psoriasis
1
Sapho Syndrome
1
Ill-defined Disorder
1
Musculoskeletal Pain
1

Novatrex Case Reports

What Novatrex safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Novatrex. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Novatrex.